Xcelerate (XCRT) Q4 2025 earnings summary

Executive summary

• Healthcare services strategy centers on medical technology and virtual health services extending physician access for patients in developing countries, through a 51% interest in ASA Africa.

• Sold the 50.1% interest in ESN Group on October 9, 2025, for $250,000; ESN is reported as discontinued operations.

• FY2025 net loss was $1.218 million, and the financial statements cite substantial doubt about the ability to continue as a going concern.

Financial highlights

• FY2025 loss from continuing operations was $687,786, versus $472,813 in FY2024; net loss was $1,218,458, versus $1,052,517.

• FY2025 operating expenses included $81,675 amortization, $428,970 goodwill and intangible asset impairment, and $177,141 general and administrative expenses.

• At December 31, 2025, cash was $363,064, total assets $363,064, total liabilities $2,405,996, and stockholders’ deficit $2,042,932.

Outlook and guidance

• Existing operational cash flow is not expected to fund anticipated operations; additional funds are needed and alternative financing sources are being explored.

• Financing may include private placements, sales of common stock or other securities, short-term loans, and stock compensation for consulting services where feasible.